This site makes use of Javascript, please enable your web browser to allow Javascript. Thank you.
Alumni | RSS | AA | Languages
 

RSS Feeds

RSS Feed - Life Sciences - Transactions - Kaye Scholer LLP

Current Feed: http://www.kayescholer.com/practice/rss.xml?p=life_sciences_transactions

> Change Feed

Kaye Scholer Advises Sandoz in Commercialization Agreement with Anacor Pharmaceuticals (07/21/14)

Kaye Scholer Advises Shareholders in €130M Sale of Activaero GmbH to Vectura Group (07/17/14)

Kaye Scholer Represents Pfizer in Acquisition of InnoPharma (07/16/14)

Dr. Gottfried Freier (07/09/14)

Dr. Gottfried Freier, Special Counsel bei Kaye Scholer, leitete von 2007 bis Mai 2012 als Managing Partner das Büro der Kanzlei in Frankfurt. Bevor er sich als Rechtsanwalt selbständig machte und 2001 zunächst Jones Day anschloss, war Dr. Freier von 1998 bis 2001 General Counsel Legal and Taxes von BASF Pharma mit weltweiter Verantwortung, sowie von 1985 bis 1998 in verschiedenen Funktionen Syndikusanwalt bei BASF (1985 - 1987 Patentabteilung, 1987 - 1993 Zentralabteilung Recht, 1993 - 1998 Zentralabteilung Steuern und Zölle). Aufgrund seiner langjährigen Tätigkeit als Unternehmensjurist in der Chemie- und der Pharmaindustrie hat sich bei der Mandantschaft von Dr. Gottfried Freier eine entsprechende Konzentration auf diese Branchen herausgebildet. Sein Beratungsspektrum umfasst vor allem die Bereiche Merger & Acquisitions, Gesellschaftsrecht, Technologietransaktionen (u.a. Lizenz- und Kooperationsverträge).

Kaye Scholer Advises on Sale of Pharmalink Consulting to Genpact (07/08/14)

Kaye Scholer Honored With 14 Practice and 48 Lawyer Rankings in Chambers USA 2013 (07/07/14)

Sandoz to Acquire Fougera Pharmaceuticals for $1.5B (06/13/14)

Kaye Scholer Advises Pfizer in Exclusive Worldwide Licensing Agreement with Gliknik (06/13/14)

Andres Liivak (06/06/14)

Andres Liivak is the Co-Chair of Kaye Scholer’s Life Sciences Industry Group and a Partner in the firm’s Corporate Department. Working together with the firm’s highly regarded, collaborative, multidisciplinary life sciences team, Andres helps life sciences healthcare industry clients develop comprehensive solutions and manage risk to achieve their business objectives. In his practice, Andres focuses on putting in place new deals as well as counseling with respect to and renegotiating existing transactions, including:

  • Priority, high value deals – examples include in-licenses of blockbuster drugs; acquisitions of target companies and products, including with sales force; divestures of approved products together with supply chain transition; collaborative development and commercialization license arrangements; contentious renegotiation of major commercial contracts relating to key products; and settlement of major IP and contract litigation with business deals.
  • Deals outside a client's comfort zone or recent experience – examples include co-promotion arrangements and companion diagnostic deals.
  • Unusually complex, novel deals – some recent examples include multi-party, multi-product collaborations involving co-development, co-commercialization and exclusive supply arrangements.

Sydney E. Unger (05/29/14)

Sydney Unger is the former Chair of the Tax Department. He practices in the area of tax law with a concentration in renewable energy, corporate and joint venture matters. He has considerable experience in working with clients in renewable energy project financing, mergers and acquisitions, corporate restructuring and bankruptcy workouts, leveraged leasing transactions and IRS and New York controversy matters.

Subscribe

 
 
Praxisgruppen Practice Groups Industry Groups Regional Groups Pro Bono Berater Sozietät Careers Diversity Pro Bono Newsroom Veranstaltungen Büros